Moderna (MRNA) FY2020 results: revenue $803 million, up 1239.0% on the year
Moderna, Inc. (MRNA) reported revenue of $803 million for fiscal 2020, the year ended 31 December 2020, up 1239.0% on the year before. Net income was -$747 million, and diluted earnings per share $-1.96. The figures are the company's own, from the 10-K it filed with the SEC on 26 February 2021.
Revenue
$803 million
+1,239.0% on the year
FY2016FY2020
Operating margin
-95.0%
-909.5% a year earlier
FY2016FY2020
Net income
-$747 million
FY2016FY2020
Diluted EPS
-$1.96
FY2016FY2020
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2020
FY2019
FY2018
On the year
Last 8 years
Revenue
803
60.0
135
+1,239.0%
Cost of revenue
8.0
0.0
0.0
Gross profit
795
60.0
135
+1,225.7%
Gross margin
99.0%
100.0%
100.0%
Research and development
1,370
496
454
+176.1%
Operating income
-763
-546
-413
Operating margin
-95.0%
-909.5%
-306.0%
Pre-tax income
-744
-515
-384
Income tax
3.0
-1.0
0.3
Net income
-747
-514
-385
Net margin
-93.0%
-856.7%
-284.8%
Diluted EPS
-$1.96
-$1.55
-$4.95
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2020
FY2019
FY2018
On the year
Last 8 years
Operating cash flow
2,027
-459
-331
Capital expenditure
68.0
32.0
106
+112.5%
Free cash flow
1,959
-491
-437
Free cash flow margin
243.8%
-818.3%
-323.3%
Cash from investing
-1,672
-15.0
-372
Cash from financing
2,033
52.0
1,227
+3,810.0%
Depreciation and amortisation
31.0
31.0
24.9
-0.1%
Share-based compensation
93.0
81.1
72.6
+14.7%
Buybacks
0.0
0.0
n/a
Diluted shares, weighted
381m
331m
n/a
+15.1%
Shares outstanding at period end
399m
337m
329m
+18.5%
Balance sheet
$ million
FY2020
FY2019
FY2018
On the year
Last 8 years
Shareholders' equity
2,561
1,175
1,530
+118.0%
Redeemable equity
n/a
n/a
0.0
Debt
0.0
0.0
n/a
Operating lease liabilities
97.0
93.7
n/a
+3.5%
Finance lease liabilities
110
38.7
n/a
+184.0%
Other liabilities
4,569
282
432
+1,518.6%
Total liabilities and equity
7,337
1,589
1,962
+361.6%
Fixed assets
n/a
n/a
212
Investments
2,623
1,027
1,036
+155.3%
Cash and equivalents
2,624
236
658
+1,012.4%
Receivables
1,391
5.4
11.7
+25,799.8%
Inventory
47.0
0.0
n/a
Other assets
653
321
44.1
+103.3%
Total assets
7,337
1,589
1,962
+361.6%
10-K for the year ended 31 December 2020, filed 26 February 2021: the filing.